The Food and Drug Administration (FDA) is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act amends and updates the Pediatric Research Equity Act (PREA). RACE Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This paper discusses the need for and the importance of pediatric research, the RACE Act, and how it applies to precision medicine.
Explore related content and topics
White Paper
Global Pediatric Drug Development Collaboration Part One
The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is…
Blog
Ask the Experts: How Can We Ensure Pediatric Oncology is at the Forefront of Legislation?
LeAnn joined PRA in October 2018 as a Senior Project Manager, working primarily on oncology clinical trials. We sat down with her to hear her…
Page
Pediatrics
PRA's highly specialized, patient-focused experts bring innovation to pediatric clinical design, ensuring safe, pediatric-tested treatments for…